35 results about "Pericyte" patented technology

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.

The application discloses a use of a solute carrier family 25A33 gene in preparation of a medicament for treating presbycusis, and the use is achieved by enhancing SLC25A33 expression on an endolymphatic vascular stripe, by maintaining mitochondrial function stability of pericyte cells around the vascular stripe, by reducing active oxygen free radical (ROS) generation, and by blocking TGFbeta / SMAD pathway-mediated pericyte differentiation, so as to protect the integrity of the blood labyrinth barrier. Animal experiments show that overexpression of SLC25A33 can significantly reduce the hearing threshold of a presbycusis model mouse, protect the structure of the blood labyrinth barrier, and improve the expression of tight junction proteins, and the SLC25A33 gene has the potential to treat presbycusis.

The present invention relates to pharmaceutical compounds and formulations comprising said compounds, wherein said compounds have the structure according to Formula I or II. The compounds and formulations are suitable for use as medicaments for the prevention or treatment of diseases or conditions characterized by percutaneous cell dysfunction, detachment and / or loss, for medical treatment for vascular stabilization, for treatment for promoting, restoring or maintaining attachment of percutaneous cells to blood vessels, and / or for the treatment of vascular-related diseases in patients. (I) (II)

Provided is a structure composed of a cell population comprising endothelial cells, astrocytes and pericytes, and a 3D (three dimensional) cell growth material within which the cell population is located. The structure has a TEER value of at least 450 Ω / cm2. The cells of the structure may be derived from the brain. The cells may be human cells, and in particular may be primary derived non-immortalised cells. The structure is particularly suited for use in a model of the blood brain barrier, and the invention also provides such a model. The structure is located in a container, in which it separates a first chamber located on a first side of the structure and a second chamber located on a second side of the structure. The first and second chambers respectively contain first and second liquids in contact with first and second sides of the structure. The liquids mimic the brain extracellular fluid and the blood. The blood brain barrier model provided may be used in models of brain disease, and to investigate uptake of agents into the brain or diseased brain.

The invention discloses a pericyte targeting active peptide and application thereof in preparation of antitumor drugs, and relates to the technical field of medicines. The percutaneous cell targeting active peptide is obtained by condensation of NKX2-3 fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP), and the fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP) are respectively Z-GP-NB1, Z-GP-NB2, Z-GP-NB3, Z-GP-NB4 The percutaneous cell targeting active peptide can effectively block the transcriptional activity of NKX2-3, recover the contractility of tumor percutaneous cells and enhance the local vascular tension of tumors, so that the tumor distal metastasis is inhibited, and the percutaneous cell targeting active peptide is expected to be applied to the treatment of patients with malignant tumors accompanied by the distal metastasis.

The present invention relates to a microfluidic device configured to study epithelial and / or endothelial barrier function in a human 3D cell microtissue model, while simultaneously allowing for the application of mechanical stimuli such as luminal flow and / or lateral flow. Embodiments include three cultures representing the maternal-fetal interface (placental barrier): human umbilical vein endothelial cells (HUVEC), human placental fibroblasts (HPF), and human placental pericytes (HPP), as well as a ductal interface composed of human primary mammary gland-derived endothelial cells, fibroblasts, and epithelial layer (MCF10). The model is expandable to include tumors (cell line-derived or patient-derived). The present invention further relates to a method for fabricating a human 3D vascular microtissue model using a microfluidic device according to the present invention, and to the use of a human 3D vascular microtissue model for, for example, studying the effects of cell barrier function (solute permeability), interstitial flow, luminal flow and / or lateral flow, and epithelial and / or endothelial barrier function (solute permeability), and extravascular matrix properties (diffusivity, stiffness, transport of molecules, antibodies and / or cells, and matrix proteins). The present invention further relates to a method for presenting a pre-eclampsia (disease) model of the placental barrier, and means for testing drug therapies.

The application provides a specific single biomarker NADH dehydrogenase alpha subcomplex subunit 4-L2 (NDUFA4L2) for detecting pericytes. The biomarker is located in the mitochondria of pericytes. The application also provides application of NDUFA4L2 in pericyte identification. The specific single biomarker NDUFA4L2 provided by the application has a pericyte recognition accuracy of more than 90%, which is higher than the accuracy of pericyte recognition of the previously generally considered pericyte marker, and can be used as a novel single pericyte biomarker with higher specificity.

The present disclosure is directed to methods of genetically subtyping peripheral t-cell lymphoma.

This product is an eye beauty device that stimulates the cells around the eyes with microcurrents, thereby promoting blood circulation and providing beauty benefits.

The present invention relates to a pharmaceutical compound and a formulation comprising the compound, wherein the compound is of formula I or II: The present invention relates to a pharmaceutical compound and a formulation having the structure shown in JPEG2026522984000107.jpg75161. The compound and the formulation are suitable for pharmaceutical use in the prevention or treatment of diseases or disorders characterized by pericyte dysfunction, detachment and / or loss; in therapeutic treatments for vascular stabilization; in treatments for promoting, restoring or maintaining pericyte adhesion to blood vessels; and / or in the treatment of vascular-related diseases in patients.

The invention relates to the technical field of cell therapy, and particularly discloses a repairable fibroblast preparation for treating pelvic organ prolapse. The active ingredients of the preparation are fibroblasts which highly express HAS1, POLR3G and DDR2 at the same time and do not express alpha-smooth muscle actin, and the preparation is compatible with pharmaceutic adjuvants such as normal saline, human serum albumin and dimethyl sulfoxide. The dosage form of the composition comprises an injection and a gel containing a hyaluronic acid matrix. The preparation method comprises the following steps: performing enzymolysis treatment to obtain primary cells, promoting repair phenotypic differentiation through estrogen induction, purifying target cells by adopting a fluorescence labeling flow sorting technology, and performing amplification in a serum-free culture medium to prepare a final preparation. According to the preparation, through the synergistic effect of fibroblasts and pericytes and the perivascular positioning characteristic, targeted repair of pelvic floor supporting tissue can be achieved; according to the preparation method, the cell phenotype stability and the preparation reproducibility are ensured by optimizing process parameters and quality control standards.

This invention discloses a combination of biomarkers, a kit, and their applications for detecting hypertrophic scars (HTS). The biomarker combination includes a core biomarker and / or auxiliary biomarker 1 and / or auxiliary biomarker 2; the core biomarker is ABCC9 and CSPG4, auxiliary biomarker 1 is RGS5 and ACTA2, and auxiliary biomarker 2 is PDGFRB and TRPC6. This invention also provides a kit containing the above biomarker combination detection reagents and a drug screening method. This invention reveals for the first time that pathological pericytes are the core fibrotic cells in HTS, breaking through the traditional understanding that fibroblasts are the dominant cells. By targeting and inhibiting the abnormal activation, proliferation, and transdifferentiation of pericytes into myofibroblasts, the generation of myofibroblasts and matrix deposition are curbed at the source, providing a new strategy for precision treatment of HTS. Compared with traditional therapies, this approach has higher specificity and can achieve early molecular warning and quantitative detection of trace tissues for HTS, effectively overcoming the lag and subjectivity of clinical morphological diagnosis.

The application provides a preparation method of pericyte-like mesenchymal stem cell exosome and application thereof in a diabetic wound surface, and relates to the fields of biotechnology, nanomedicine and regenerative medicine. The preparation method of the pericyte-like mesenchymal stem cell exosome comprises the following steps: providing pericyte-like mesenchymal stem cells (P-MSC), and inducing culture of mesenchymal stem cells (MSC) in a culture medium containing an effective concentration of a nitric oxide (NO) donor to obtain the pericyte-like mesenchymal stem cells (P-MSC). The application has the advantages of high targeting and precise repair. The P-MSC-Exo prepared by the application is rich in PDGFR-beta on the surface, so that the P-MSC-Exo can be specifically targeted and enriched at the damaged blood vessel endothelium expressing the ligand PDGF-BB, and precise delivery is achieved. The content can directly repair the mitochondrial damage of endothelial cells, and restore the cell function from the root.

The invention provides a biomarker screening method and system for radiotherapy-immunity pneumonia prediction, and relates to the technical field of biomedicine. Aiming at the problem that the timeliness and the specificity of the existing radiotherapy-immunity pneumonia diagnosis cannot be considered at the same time, the method comprises the following steps: separating peripheral blood T cells of a radiotherapy-immunity pneumonia group and a control group, carrying out T cell clustering annotation in combination with single-cell secretory proteomics, an R language and an ImMen database, and screening a key T cell subset Tc17 by utilizing an Augur algorithm; the method comprises the following steps: determining pericytes as key interaction cells of Tc17 through cell interaction analysis, and screening a radiotherapy specific up-regulation gene MFAP4; and carrying out difference analysis on the Mfap4hi week cell subpopulation, and screening out a biomarker gene set containing 18 genes on the basis of an elastic network algorithm in combination with 3-fold nested cross validation. The invention provides a key basis for early prediction and accurate intervention of radiotherapy-immunity pneumonia, and has the advantages of high specificity and strong repeatability.

The invention discloses an application of a chemical small molecule composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) in preparation of a medicine for treating blood-brain barrier repair. The invention discloses a specific combined chemical small molecule and an induction scheme thereof. The specific combined chemical small molecule can be used for efficiently reprogramming fibroblasts from somatic cells into PCLCs. Furthermore, the application potential of the obtained PCLCs in blood brain barrier repair is verified, a new strategy for avoiding the ethics and safety problems of a traditional reprogramming technology is provided for obtaining pericytes, and an experimental foundation is laid for developing cell drugs for repairing blood brain barriers.

The invention discloses application of TPM1 in treatment of wet age-related macular degeneration. Research finds that TPM1 promotes angiogenesis, inflammation and fibrosis in eyes. The anti-angiogenesis effect of inhibiting TPM1 is similar to that of inhibiting VEGF-A, but the effect of inhibiting TPM1 is more remarkable in the aspect of reducing inflammation and fibrosis, so that the compound can be used as a potential target for treating wAMD. In addition, single cell sequencing finds that the TPM1 has high specific expression in CNV focus peripheral cells of a wAMD patient; functional experiments prove that the TPM1 is knocked down to significantly inhibit periodontocyte proliferation and migration, which prompts that the TPM1 participates in wAMD progress by regulating periodontocyte functions and does not respond to anti-VEGF treatment.

In particular, compositions comprising iPSC-derived parietal cell precursors (iMPCs) generated using NK3 homeobox 1 (NKX3.1; parietal cell fate-determining transcription factor) and methods for their preparation and use are described herein. In addition, in particular, methods for maturing iMPCs into functional parietal cell subtypes, including smooth muscle cells, perivascular cells, and fibroblasts, as well as methods for increasing angiogenesis, angiogenesis, and cell junctions, are described herein. iMPCs mediate the formation of functional blood vessels when transplanted together with endothelial cells (ECs); thus, methods for modeling vascular diseases (e.g., 3D vascular organoids (VOs)) and therapeutic vascularization, comprising a method of administering iMPCs and ECs and a step of administering iMPCs and ECs, are also described herein.

The application belongs to the technical field of medicine, and particularly relates to pericyte-derived mitochondria-rich extracellular vesicles and application thereof in ischemic brain injury. The extraction method of the extracellular vesicles comprises the following steps: (1) cutting a cerebral cortex part, adding collagenase type II and DNase I for digestion, and then adding a gradient separation liquid to separate pericytes; (2) spreading the pericytes on a culture dish coated with collagen type IV and culturing in a pericyte culture medium; (3) when the cell confluence degree reaches 80% to 90%, the cell culture medium is replaced with a fresh culture medium without exosomes FBS, the cells are subjected to OGD treatment and then reoxygenated for 24 hours, the culture supernatant is collected, and the culture supernatant is centrifuged to obtain the extracellular vesicles. The PC-EVs obtained after OGD stress are found to be capable of protecting the brain from ischemic stroke for the first time, and have important reference significance for researching and treating drugs related to ischemic brain injury.

The invention discloses a chemical reprogramming multifunctional mesenchymal stromal cell based on a glycyrrhizic acid solubilizing technology and application thereof. According to the invention, a specific chemical small molecule combination is adopted, and human fibroblasts are reprogrammed into multifunctional mesenchymal stromal cells (CiMFSCs) with high expression of NSMF / NAV2 / BMP4 / LAMA2 and other genes. The key advantage of the CiMFSCs is that the CiMFSCs can target a plurality of key links of cerebral arterial thrombosis treatment at the same time, including promotion of neurogenesis, angiogenesis, repair of blood brain barrier (BBB) and exertion of paracrine function, so that effective neural function recovery is finally realized. Compared with umbilical cord mesenchymal stem cells, neural stem cells differentiated by iPSC, vascular endothelial cells differentiated by iPSC and pericytes differentiated by iPSC, the CiMFSCs show a remarkable and superior treatment effect in a stroke model mouse: the CiMFSCs can remarkably reduce the cerebral infarction volume, improve the survival rate of the model mouse, improve the neurobehavioral score and realize comprehensive repair of nerve and blood vessel units.

This invention relates to the field of biomedicine, and particularly to the application of anti-VLA4 therapy in antidepressant treatment by inhibiting the migration of γδ T cells to the central nervous system. This invention utilizes anti-VLA4 antibody treatment to reduce the infiltration of γδ T cells into the meninges and brain parenchyma of mice, revealing that anti-VLA4 inhibition of peripheral T cell migration can block CUMS-induced depressive-like behaviors, providing a novel strategy for the treatment of depression.

The invention discloses a method for reprogramming fibroblasts into pericyte-like cells (PCLCs) through a chemical small molecule combination, and an application of the method in preparation of a medicine for treating vascular leakage diseases, and particularly relates to a method for reprogramming fibroblasts into the PCLCs. According to the preparation method, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is regulated and controlled in a time sequence mode, and fibroblasts are efficiently induced into PCLCs with high expression of pericyte related marker genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, NQO1 and QPRT. When the obtained PCLCs is used for treating vascular leakage diseases, multiple biological functions such as inflammation resistance, oxidation resistance, immunoregulation and tissue barrier protection can be achieved, so that the pathological condition is improved, and the death rate is reduced. The invention provides a novel safe cell drug strategy without gene manipulation for the treatment of vascular leakage diseases.

This application relates to the fields of image processing and medical image analysis technology, and discloses a method and system for detecting pericyte apoptosis in diabetic retinopathy images. The method includes acquiring a diabetic retinopathy image to be processed using a microscopic image acquisition device; identifying non-cell-covered blank background areas in the diabetic retinopathy image; extracting color information and grayscale value information from the blank background areas; calculating the color deviation information relative to preset standard color information, and calculating the grayscale value deviation information relative to preset standard grayscale value information; generating correction parameters for correcting the diabetic retinopathy image based on the color deviation information and grayscale value deviation information; and correcting the diabetic retinopathy image based on the correction parameters. This application is beneficial for improving the accuracy of subsequent pericyte apoptosis detection. This invention was supported by the Shandong Provincial Natural Science Foundation Youth Project (Project No.: ZR2022QH231).

This invention provides an anti-human CXCL13 rabbit monoclonal antibody, its preparation method, and its application, belonging to the field of immunoglobulin technology. This invention provides an anti-human CXCL13 rabbit monoclonal antibody that can specifically bind to the CXCL13 protein, significantly improving the specificity and sensitivity of immunoassay. It is suitable for preparing immunohistochemical detection kits and can accurately detect CXCL13 protein expression, providing a reliable tool for the diagnosis of diseases such as angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

The invention discloses an extracellular vesicle targeting pericerebral cells and a medicine, and relates to the technical field of biological medicines. According to the extracellular vesicles targeting the pericerebral cells, the extracellular vesicles can be delivered to the pericerebral cells in a targeted mode through the targeting ligand modified on the surface of the extracellular vesicles and the cell surface receptor capable of being specifically combined with the pericerebral cells, and a new delivery tool and therapeutic drug selection are provided for treatment of central nervous system related diseases.

The present invention relates to a method for identifying a subject who has chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), small lymphocytic lymphoma (SLL), or acute lymphoblastic leukemia (ALL) who responds to treatment with an anti-CD19 antibody, said method comprising: a) providing a blood sample obtained from said subject prior to treatment with said anti-CD19 antibody, b) determining the level of at least one biomarker in said sample selected from the group consisting of i) peripheral NK cell count, and ii) CD16 expression levels in peripheral NK cells, c) comparing the level of said at least one biomarker in said sample to a predetermined cutoff level, wherein levels of said at least one biomarker at or above the predetermined cutoff level are indicative of a subject who would benefit from treatment with an anti-CD19 antibody.This disclosure also relates to a method for selecting a patient for treatment in accordance with the above and to the use of an anti-CD19 antibody for the treatment of such patient.

The present invention addresses the problem of providing: a blood-brain barrier model that can be produced in a relatively simple manner and in which a physiological barrier function and selective permeability are reproduced; and a method for producing the blood-brain barrier model.　A blood-brain barrier model in which a physiological barrier function and selective permeability are reproduced can be produced in a relatively simple manner in a blood-brain barrier model having three cell layers of perisites, astrocytes, and vascular endothelial cells by culturing vascular endothelial cells so as to form a sheet structure on the surface of a porous membrane and so that perisites are present in an internal structure layer of the porous membrane.

The invention discloses a double-gene-labeled cell conditional knockout mouse model and a construction method thereof, and belongs to the technical field of animal model construction. The construction method comprises the following steps: respectively constructing an F1-generation PDGFRa-Cre mouse, an F1-generation CD34-Dre mouse and an F1-generation CAGpromoter-loxP-stop-loxP-Rox-stop-Rox-DTR mouse, carrying out mutual breeding to obtain an F2-generation mouse, and screening the mice which express DTR in cells which are co-expressed by a CD34 gene and a PDGFRa gene. The double-gene marker cell conditional knockout mouse model is constructed through CD34 + PDGFR alpha + teterocyte ablation, specific gene knockout of double-gene positive expression cells of a target tissue is achieved, and an experimental tool can be provided for verifying feasibility of teterocyte targeted therapy when the mouse model is used for an acute lung injury disease related animal model.

To provide a novel agent for increasing the expression of adhesion-related factors between vascular pericytes and vascular endothelial cells, and to provide a screening method of a component for increasing the expression of the adhesion-related factors.SOLUTION: Provided are an agent for increasing the expression of adhesion-related factors between vascular pericytes and vascular endothelial cells, containing the extract of S.officinalis as an active ingredient; and a screening method comprising selecting a skin color-improving component using the adhesion state between vascular pericytes and vascular endothelial cells as an index.SELECTED DRAWING: None

The present invention addresses the problem of providing a new ischemic disease treatment strategy targeting pericytes. As a solution, the present invention provides an inflammation suppressant or a tissue protective agent for ischemic injury, each including an inhibitor which blocks ATP-sensitive potassium (KATP) channels present in a pericyte. In particular, the KATP channel is composed of pore-forming KIR6.1 and regulatory SUR2 subunits, and it is preferable for the inhibitor to act on the KIR6.1. The inflammation suppressant or the tissue protective agent for ischemic injury is preferably used in the treatment of ischemic diseases such as cerebral infarction or ischemic cardiac disease.

This invention discloses the application of TPM1 in the treatment of wet age-related macular degeneration (wAMD). The study found that TPM1 promotes angiogenesis, inflammation, and fibrosis in the eye. The anti-angiogenic effect of inhibiting TPM1 is similar to that of inhibiting VEGF-A, but the effect of inhibiting TPM1 in reducing inflammation and fibrosis is more significant, thus making it a potential target for the treatment of wAMD. Furthermore, single-cell sequencing revealed that TPM1 is specifically highly expressed in pericytes of CNV lesions in wAMD patients; functional experiments confirmed that knocking down TPM1 significantly inhibits pericyte proliferation and migration, suggesting that it participates in wAMD progression and unresponsiveness to anti-VEGF therapy by regulating pericyte function.